Do analysts prefer BCAB or MYNZ?

BioAtla presently has a consensus target price of $200.00, indicating a potential upside of 5,081.35%. Given BioAtla's stronger consensus rating and higher possible upside, research analysts clearly believe BioAtla is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAtla 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is BCAB or MYNZ more profitable?

Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -325.64% Mainz Biomed N/A N/A N/A

Is CLRB or BCAB more profitable?

BioAtla's return on equity of 0.00% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cellectar Biosciences N/A -349.24% -153.18% BioAtla N/A N/A -325.64%

Which has better earnings and valuation, BCAB or KZIA?

Novogen has lower revenue, but higher earnings than BioAtla. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioAtla $2M 3.20 -$59.61M -$41.72 N/A Novogen $30K 785.40 -$13.41M N/A N/A

Is BCAB or KZIA more profitable?

Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -325.64% Novogen N/A N/A N/A

Do analysts prefer TPST or BCAB?

BioAtla has a consensus price target of $200.00, suggesting a potential upside of 5,081.35%. Given BioAtla's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than Tempest Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 BioAtla 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is TPST or BCAB more profitable?

BioAtla's return on equity of 0.00% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tempest Therapeutics N/A -355.61% -121.21% BioAtla N/A N/A -325.64%

Do analysts prefer XCUR or BCAB?

BioAtla has a consensus target price of $200.00, suggesting a potential upside of 5,081.35%. Given BioAtla's stronger consensus rating and higher probable upside, analysts plainly believe BioAtla is more favorable than Exicure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 BioAtla 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is XCUR or BCAB more profitable?

BioAtla's return on equity of 0.00% beat Exicure's return on equity. Company Net Margins Return on Equity Return on Assets Exicure N/A -179.41% -64.37% BioAtla N/A N/A -325.64%

BioAtla (BCAB) Competitors

$3.86 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$3.80 -0.05 (-1.42%)

As of 06/12/2026 06:42 PM Eastern

Compare

BCAB vs. MYNZ, CLRB, KZIA, TPST, and XCUR

Should you buy BioAtla stock or one of its competitors? MarketBeat compares BioAtla with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioAtla include Mainz Biomed (MYNZ), Cellectar Biosciences (CLRB), Novogen (KZIA), Tempest Therapeutics (TPST), and Exicure (XCUR). These companies are all part of the "pharmaceutical products" industry.

How does BioAtla compare to Mainz Biomed?

BioAtla (NASDAQ:BCAB) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

77.2% of BioAtla shares are owned by institutional investors. 9.3% of BioAtla shares are owned by insiders. Comparatively, 18.2% of Mainz Biomed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

BioAtla has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

Mainz Biomed has lower revenue, but higher earnings than BioAtla. BioAtla is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$2M	3.20	-$59.61M	-$41.72	N/A
Mainz Biomed	$659.94K	23.75	-$21.65M	-$65.60	N/A

In the previous week, BioAtla had 1 more articles in the media than Mainz Biomed. MarketBeat recorded 1 mentions for BioAtla and 0 mentions for Mainz Biomed. BioAtla's average media sentiment score of 1.87 beat Mainz Biomed's score of 0.00 indicating that BioAtla is being referred to more favorably in the media.

Company	Overall Sentiment
BioAtla	Very Positive
Mainz Biomed	Neutral

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-325.64%
Mainz Biomed	N/A	N/A	N/A

BioAtla presently has a consensus target price of $200.00, indicating a potential upside of 5,081.35%. Given BioAtla's stronger consensus rating and higher possible upside, research analysts clearly believe BioAtla is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

BioAtla beats Mainz Biomed on 9 of the 14 factors compared between the two stocks.

How does BioAtla compare to Cellectar Biosciences?

Cellectar Biosciences (NASDAQ:CLRB) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

In the previous week, Cellectar Biosciences had 1 more articles in the media than BioAtla. MarketBeat recorded 2 mentions for Cellectar Biosciences and 1 mentions for BioAtla. BioAtla's average media sentiment score of 1.87 beat Cellectar Biosciences' score of 1.43 indicating that BioAtla is being referred to more favorably in the news media.

Company	Overall Sentiment
Cellectar Biosciences	Positive
BioAtla	Very Positive

BioAtla's return on equity of 0.00% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-349.24%	-153.18%
BioAtla	N/A	N/A	-325.64%

16.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 2.6% of Cellectar Biosciences shares are held by company insiders. Comparatively, 9.3% of BioAtla shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Cellectar Biosciences has higher earnings, but lower revenue than BioAtla. Cellectar Biosciences is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A
BioAtla	$2M	3.20	-$59.61M	-$41.72	N/A

Cellectar Biosciences has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, BioAtla has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market.

Cellectar Biosciences presently has a consensus target price of $11.00, indicating a potential upside of 393.27%. BioAtla has a consensus target price of $200.00, indicating a potential upside of 5,081.35%. Given BioAtla's higher possible upside, analysts clearly believe BioAtla is more favorable than Cellectar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

BioAtla beats Cellectar Biosciences on 8 of the 14 factors compared between the two stocks.

How does BioAtla compare to Novogen?

BioAtla (NASDAQ:BCAB) and Novogen (NASDAQ:KZIA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

In the previous week, Novogen had 2 more articles in the media than BioAtla. MarketBeat recorded 3 mentions for Novogen and 1 mentions for BioAtla. BioAtla's average media sentiment score of 1.87 beat Novogen's score of 0.96 indicating that BioAtla is being referred to more favorably in the media.

Company	Overall Sentiment
BioAtla	Very Positive
Novogen	Positive

77.2% of BioAtla shares are held by institutional investors. Comparatively, 30.9% of Novogen shares are held by institutional investors. 9.3% of BioAtla shares are held by company insiders. Comparatively, 1.0% of Novogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-325.64%
Novogen	N/A	N/A	N/A

BioAtla has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Novogen has a beta of 2.17, indicating that its share price is 117% more volatile than the broader market.

BioAtla presently has a consensus target price of $200.00, suggesting a potential upside of 5,081.35%. Novogen has a consensus target price of $23.75, suggesting a potential upside of 66.32%. Given BioAtla's higher probable upside, equities analysts clearly believe BioAtla is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Novogen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Novogen has lower revenue, but higher earnings than BioAtla.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$2M	3.20	-$59.61M	-$41.72	N/A
Novogen	$30K	785.40	-$13.41M	N/A	N/A

Summary

Novogen beats BioAtla on 7 of the 12 factors compared between the two stocks.

How does BioAtla compare to Tempest Therapeutics?

Tempest Therapeutics (NASDAQ:TPST) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

BioAtla's return on equity of 0.00% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-355.61%	-121.21%
BioAtla	N/A	N/A	-325.64%

22.5% of Tempest Therapeutics shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 36.3% of Tempest Therapeutics shares are held by company insiders. Comparatively, 9.3% of BioAtla shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Tempest Therapeutics has higher earnings, but lower revenue than BioAtla. Tempest Therapeutics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A
BioAtla	$2M	3.20	-$59.61M	-$41.72	N/A

Tempest Therapeutics has a beta of -1.85, indicating that its share price is 285% less volatile than the broader market. Comparatively, BioAtla has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market.

BioAtla has a consensus price target of $200.00, suggesting a potential upside of 5,081.35%. Given BioAtla's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than Tempest Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Tempest Therapeutics and Tempest Therapeutics both had 1 articles in the media. Tempest Therapeutics' average media sentiment score of 1.87 equaled BioAtla'saverage media sentiment score.

Company	Overall Sentiment
Tempest Therapeutics	Very Positive
BioAtla	Very Positive

Summary

BioAtla beats Tempest Therapeutics on 8 of the 12 factors compared between the two stocks.

How does BioAtla compare to Exicure?

Exicure (NASDAQ:XCUR) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

In the previous week, Exicure had 4 more articles in the media than BioAtla. MarketBeat recorded 5 mentions for Exicure and 1 mentions for BioAtla. BioAtla's average media sentiment score of 1.87 beat Exicure's score of 0.57 indicating that BioAtla is being referred to more favorably in the news media.

Company	Overall Sentiment
Exicure	Positive
BioAtla	Very Positive

BioAtla's return on equity of 0.00% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-179.41%	-64.37%
BioAtla	N/A	N/A	-325.64%

Exicure has higher earnings, but lower revenue than BioAtla. Exicure is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	$500K	35.42	-$4.95M	-$1.55	N/A
BioAtla	$2M	3.20	-$59.61M	-$41.72	N/A

BioAtla has a consensus target price of $200.00, suggesting a potential upside of 5,081.35%. Given BioAtla's stronger consensus rating and higher probable upside, analysts plainly believe BioAtla is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Exicure has a beta of 3.53, indicating that its stock price is 253% more volatile than the broader market. Comparatively, BioAtla has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

42.8% of Exicure shares are owned by institutional investors. Comparatively, 77.2% of BioAtla shares are owned by institutional investors. 52.8% of Exicure shares are owned by insiders. Comparatively, 9.3% of BioAtla shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

BioAtla beats Exicure on 8 of the 15 factors compared between the two stocks.

Get BioAtla News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCAB vs. The Competition

Export

Metric	BioAtla	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.41M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-0.09	20.00	24.00	24.42
Price / Sales	3.20	303.75	533.77	123.88
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	-0.14	8.32	10.55	6.82
Net Income	-$59.61M	$23.94M	$3.57B	$337.56M
7 Day Performance	16.62%	1.84%	0.59%	1.16%
1 Month Performance	-9.60%	-0.04%	1.55%	3.16%
1 Year Performance	-80.96%	44.82%	25.41%	30.60%

BioAtla Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCAB BioAtla	2.7501 of 5 stars	$3.86 flat	$200.00 +5,081.3%	-81.0%	$6.41M	$2M	N/A	60	Positive News Gap Down
MYNZ Mainz Biomed	N/A	$2.20 -5.6%	N/A	-5.5%	$19.93M	$659.94K	N/A	30	High Trading Volume
CLRB Cellectar Biosciences	4.4075 of 5 stars	$2.40 -4.4%	$11.00 +358.3%	-82.0%	$19.14M	N/A	N/A	10	Positive News
KZIA Novogen	2.2224 of 5 stars	$11.26 -1.2%	$21.00 +86.5%	+53.5%	$18.99M	$30K	N/A	12	Gap Down
TPST Tempest Therapeutics	2.8077 of 5 stars	$1.28 +0.8%	N/A	-80.9%	$18.96M	N/A	N/A	20	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCAB) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioAtla (BCAB) Competitors

BCAB vs. MYNZ, CLRB, KZIA, TPST, and XCUR

How does BioAtla compare to Mainz Biomed?

Summary

How does BioAtla compare to Cellectar Biosciences?

Summary

How does BioAtla compare to Novogen?

Summary

How does BioAtla compare to Tempest Therapeutics?

Summary

How does BioAtla compare to Exicure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB vs. The Competition

BioAtla Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioAtla (BCAB) Competitors

BCAB vs. MYNZ, CLRB, KZIA, TPST, and XCUR

How does BioAtla compare to Mainz Biomed?

Do institutionals & insiders have more ownership in BCAB or MYNZ?

Which has more volatility and risk, BCAB or MYNZ?

Which has higher earnings and valuation, BCAB or MYNZ?

Does the media favor BCAB or MYNZ?

Is BCAB or MYNZ more profitable?

Do analysts prefer BCAB or MYNZ?

Summary

How does BioAtla compare to Cellectar Biosciences?

Does the media favor CLRB or BCAB?

Is CLRB or BCAB more profitable?

Do insiders & institutionals have more ownership in CLRB or BCAB?

Which has higher earnings & valuation, CLRB or BCAB?

Which has more volatility and risk, CLRB or BCAB?

Do analysts recommend CLRB or BCAB?

Summary

How does BioAtla compare to Novogen?

Does the media prefer BCAB or KZIA?

Do institutionals and insiders have more ownership in BCAB or KZIA?

Is BCAB or KZIA more profitable?

Which has more risk & volatility, BCAB or KZIA?

Do analysts recommend BCAB or KZIA?

Which has better earnings and valuation, BCAB or KZIA?

Summary

How does BioAtla compare to Tempest Therapeutics?

Is TPST or BCAB more profitable?

Do institutionals & insiders hold more shares of TPST or BCAB?

Which has preferable earnings and valuation, TPST or BCAB?

Which has more volatility and risk, TPST or BCAB?

Do analysts prefer TPST or BCAB?

Does the media favor TPST or BCAB?

Summary

How does BioAtla compare to Exicure?

Does the media favor XCUR or BCAB?

Is XCUR or BCAB more profitable?

Which has stronger valuation and earnings, XCUR or BCAB?

Do analysts prefer XCUR or BCAB?

Which has more risk & volatility, XCUR or BCAB?

Do insiders & institutionals hold more shares of XCUR or BCAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB vs. The Competition

BioAtla Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools